Clin2
NCT07787325Likely a fitNot yet recruiting

Clot-busting drug for stroke within 4.5 hours

Acute Ischemic Stroke

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests a clot-busting drug called recombinant human prourokinase for people having an ischemic stroke (a stroke from a blocked blood vessel). The drug is given through an IV within 4.5 hours of symptoms to help restore blood flow and potentially reduce disability.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
3,000 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years old or older.
  • You had a stroke caused by a blocked blood vessel (ischemic stroke) and can start treatment within 4.5 hours of symptoms starting.
  • You do not have uncontrolled high blood pressure (systolic ≥185 mmHg or diastolic ≥110 mmHg).
  • You do not have active bleeding or high risk of bleeding (e.g., recent surgery or major injury).
  • You have not had a stroke, severe head trauma, or heart attack in the last 3 months.
  • You do not have a history of bleeding in the brain, and a CT scan shows no bleeding now.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07776873Not yet recruiting· Phase 3
Clot-busting drug for stroke blockages up to 24 hours

This trial tests a medicine given through a vein to break up blood clots in medium-sized brain arteries. It may help people who had a stroke between 4.5 and 24 hours ago and cannot have the standard clot-removal procedure.

Hefei, Anhui
NCT07550296Recruiting· Phase 2
Second IV Clot-Dissolving Treatment for Major Stroke

This trial tests giving a second dose of an IV clot-dissolving medicine (prourokinase) to patients who had a stroke from a large clot but didn't improve enough after the first dose. The goal is to see if a second dose within 6 hours of stroke onset can help more patients recover.

Shenyang, None Selected
NCT07047326Recruiting
Urokinase for acute ischemic stroke within 6 hours

This trial tests whether the clot-busting drug urokinase can help people who have had an ischemic stroke (a stroke caused by a blood clot). The goal is to dissolve the clot and improve recovery, as long as treatment starts within 6 hours of the first symptoms.

Beijing, Beijing Municipality
NCT07617870Not yet recruiting· Phase 3
Pro-urokinase for Recent Posterior Brain Strokes

This trial tests a clot-dissolving medication (pro-urokinase) for people with recent strokes in the back of the brain. You would be treated 4.5 to 9 hours after symptoms start, which is beyond the typical treatment window, using special MRI patterns to identify patients most likely to benefit.

Zhengzhou, Henan
NCT06749834Recruiting· Phase 3
Clot-busting drug after stroke in people on newer blood thinners

This trial tests whether a clot-busting medication given through a vein (intravenous thrombolysis) can safely treat acute ischemic stroke within 24 hours in people who have taken a newer oral blood thinner (NOAC) within the last 4 to 48 hours.

Hangzhou, Zhejiang
NCT07389460Not yet recruiting· Phase 3
Study of a clot-busting drug before thrombectomy for stroke

This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.

Lanzhou, Gansu

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.